SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

UBS Says Fresenius’s Biopharma Performance Should Be Well Received

UBS analysts say Fresenius’s adjusted third-quarter earnings came in ahead of expectations, citing strong biopharma performance.

FRE

Related stories